These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 9844927)
1. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Moos M; Schulz R; Martin S; Benner A; Haas R Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927 [TBL] [Abstract][Full Text] [Related]
2. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159 [TBL] [Abstract][Full Text] [Related]
3. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609 [TBL] [Abstract][Full Text] [Related]
4. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. Haas R; Moos M; Karcher A; Möhle R; Witt B; Goldschmidt H; Frühauf S; Flentje M; Wannenmacher M; Hunstein W J Clin Oncol; 1994 Aug; 12(8):1685-92. PubMed ID: 7518860 [TBL] [Abstract][Full Text] [Related]
5. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Voso MT; Pantel G; Weis M; Schmidt P; Martin S; Moos M; Ho AD; Haas R; Hohaus S Br J Haematol; 2000 Jun; 109(4):729-35. PubMed ID: 10929022 [TBL] [Abstract][Full Text] [Related]
6. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261 [TBL] [Abstract][Full Text] [Related]
7. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Haas R; Brittinger G; Meusers P; Murea S; Goldschmidt H; Wannenmacher M; Hunstein W Leukemia; 1996 Dec; 10(12):1975-9. PubMed ID: 8946940 [TBL] [Abstract][Full Text] [Related]
9. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy. Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339 [TBL] [Abstract][Full Text] [Related]
10. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant. Laporte JP; Yeshurun M; Fouillard L; Labopin M; Cailliot C; Lesage S; Isnard F; Najman A; Gorin NC Leukemia; 2004 Oct; 18(10):1717-21. PubMed ID: 15295607 [TBL] [Abstract][Full Text] [Related]
11. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845 [TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099 [TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536 [TBL] [Abstract][Full Text] [Related]
14. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Berglund A; Enblad G; Carlson K; Glimelius B; Hagberg H Eur J Haematol; 2000 Jul; 65(1):17-22. PubMed ID: 10914935 [TBL] [Abstract][Full Text] [Related]
16. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related]
17. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406 [TBL] [Abstract][Full Text] [Related]
18. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Voso MT; Martin S; Hohaus S; Abdallah A; Schlenk RF; Ho AD; Haas R Bone Marrow Transplant; 2000 May; 25(9):957-64. PubMed ID: 10800063 [TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Haq R; Sawka CA; Franssen E; Berinstein NL Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]